[
  {
    "ts": null,
    "headline": "Why Johnson & Johnson Stock Still Has Room To Run",
    "summary": "Johnson & Johnson's stock still has room to rise after the recent financial results exceeded expectations. Learn how J&J is positioned for success.",
    "url": "https://finnhub.io/api/news?id=f91fa708d468ed0055cf208a7e499c4baab6bc95d328e2fd9c2318d48af28388",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754327543,
      "headline": "Why Johnson & Johnson Stock Still Has Room To Run",
      "id": 136202830,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/505129430/image_505129430.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's stock still has room to rise after the recent financial results exceeded expectations. Learn how J&J is positioned for success.",
      "url": "https://finnhub.io/api/news?id=f91fa708d468ed0055cf208a7e499c4baab6bc95d328e2fd9c2318d48af28388"
    }
  },
  {
    "ts": null,
    "headline": "Pharma CEOs downplay impact of tariffs amid rising cost concerns",
    "summary": "Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.",
    "url": "https://finnhub.io/api/news?id=5d98102ea0e588f3abf9c394b6df2055a9cbc8dd28b5e98be18977b41e173560",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754326729,
      "headline": "Pharma CEOs downplay impact of tariffs amid rising cost concerns",
      "id": 136201465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.",
      "url": "https://finnhub.io/api/news?id=5d98102ea0e588f3abf9c394b6df2055a9cbc8dd28b5e98be18977b41e173560"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock rises Monday, still underperforms market",
    "summary": "AbbVie Inc. stock rises Monday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=3fd3ae450f6cb883396a546a6cb0824671ac7ee17c6b7a47e864e6bb0e9b2dd7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754325120,
      "headline": "AbbVie Inc. stock rises Monday, still underperforms market",
      "id": 136208802,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock rises Monday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=3fd3ae450f6cb883396a546a6cb0824671ac7ee17c6b7a47e864e6bb0e9b2dd7"
    }
  },
  {
    "ts": null,
    "headline": "J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?",
    "summary": "JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.",
    "url": "https://finnhub.io/api/news?id=bd652f35b7613020e47289169149141281db27be04e3b917412a54cdce6f0f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754311860,
      "headline": "J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?",
      "id": 136200252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.",
      "url": "https://finnhub.io/api/news?id=bd652f35b7613020e47289169149141281db27be04e3b917412a54cdce6f0f38"
    }
  },
  {
    "ts": null,
    "headline": "How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?",
    "summary": "AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.",
    "url": "https://finnhub.io/api/news?id=9c132eec1758bc3561b9be905e163bf9acfd270aee745dd8f37eab5499c6e846",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754309700,
      "headline": "How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?",
      "id": 136200231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.",
      "url": "https://finnhub.io/api/news?id=9c132eec1758bc3561b9be905e163bf9acfd270aee745dd8f37eab5499c6e846"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Fund Q2 2025 Commentary",
    "summary": "Janus Henderson reviews Q2 healthcare headwinds and standout biotech picks. Learn how the fund is navigating policy shifts and finding innovation upside.",
    "url": "https://finnhub.io/api/news?id=0b87039d99d7e9cf0a9a88ab06e6861b276113fa4e554693cfbacf40d7eb67b3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754288400,
      "headline": "Janus Henderson Global Life Sciences Fund Q2 2025 Commentary",
      "id": 136196996,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172204552/image_172204552.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Janus Henderson reviews Q2 healthcare headwinds and standout biotech picks. Learn how the fund is navigating policy shifts and finding innovation upside.",
      "url": "https://finnhub.io/api/news?id=0b87039d99d7e9cf0a9a88ab06e6861b276113fa4e554693cfbacf40d7eb67b3"
    }
  }
]